Year All20242023202220212020201920182017 Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency Jul 26, 2023 Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023 Jul 19, 2023 Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701 Jun 27, 2023 Inozyme Pharma to Present at the Jefferies Healthcare Conference Jun 02, 2023 Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights May 09, 2023 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 03, 2023 Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS) Apr 14, 2023 Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference Apr 11, 2023 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer Apr 04, 2023 Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights Mar 22, 2023
Year All20242023202220212020201920182017 Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency Jul 26, 2023 Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023 Jul 19, 2023 Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701 Jun 27, 2023 Inozyme Pharma to Present at the Jefferies Healthcare Conference Jun 02, 2023 Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights May 09, 2023 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 03, 2023 Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS) Apr 14, 2023 Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference Apr 11, 2023 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer Apr 04, 2023 Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights Mar 22, 2023
Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency Jul 26, 2023
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701 Jun 27, 2023
Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights May 09, 2023
Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS) Apr 14, 2023
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer Apr 04, 2023
Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights Mar 22, 2023